Type 2 T cell responses against distinct epitopes of the desmoglein 3 ectodomain in pemphigus vulgaris.

[1]  P. Kind,et al.  Skin-infiltrating T cells display distinct inflammatory signatures in lichen planus, bullous pemphigoid and pemphigus vulgaris , 2023, Frontiers in Immunology.

[2]  K. Ghoreschi,et al.  Detection of rare autoreactive T cell subsets in patients with pemphigus vulgaris , 2022, Frontiers in Immunology.

[3]  M. Hertl,et al.  Detection of autoreactive CD4+ T cells by MHC class II multimers in HLA-linked human autoimmune diseases. , 2021, The Journal of clinical investigation.

[4]  R. Pollmann,et al.  Immunophenotyping in pemphigus reveals a Th17/Tfh17-dominated immune response promoting desmoglein1/3-specific autoantibody production. , 2020, The Journal of allergy and clinical immunology.

[5]  R. Pollmann,et al.  Autoreactive T cells in pemphigus. Perpetrator and target. , 2020, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

[6]  J. Gudjonsson,et al.  Mechanisms of skin autoimmunity: Cellular and soluble immune components of the skin. , 2020, The Journal of allergy and clinical immunology.

[7]  M. Amagai,et al.  Autoimmune bullous skin diseases, pemphigus and pemphigoid. , 2020, The Journal of allergy and clinical immunology.

[8]  J. Wrammert,et al.  Single-Cell Analysis Suggests that Ongoing Affinity Maturation Drives the Emergence of Pemphigus Vulgaris Autoimmune Disease , 2019, Cell reports.

[9]  R. Eming,et al.  Pemphigus: Current and Future Therapeutic Strategies , 2019, Front. Immunol..

[10]  K. Kridin,et al.  Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. , 2019, Autoimmunity reviews.

[11]  R. Eming,et al.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status , 2018, Drugs.

[12]  O. Sarig,et al.  The Genetics of Pemphigus Vulgaris , 2018, Front. Med..

[13]  Andrew K. Sewell,et al.  Optimized Peptide–MHC Multimer Protocols for Detection and Isolation of Autoimmune T-Cells , 2018, Front. Immunol..

[14]  R. Pollmann,et al.  TH1/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus. , 2018, The Journal of allergy and clinical immunology.

[15]  R. Pollmann,et al.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches , 2018, Clinical Reviews in Allergy & Immunology.

[16]  Jie Zheng,et al.  Pivotal Role of Lesional and Perilesional T/B Lymphocytes in Pemphigus Pathogenesis. , 2017, The Journal of investigative dermatology.

[17]  Carlo José Freire Oliveira,et al.  Th1/Th17-Related Cytokines and Chemokines and Their Implications in the Pathogenesis of Pemphigus Vulgaris , 2017, Mediators of inflammation.

[18]  Jana Langenhan,et al.  Proteomic Analysis of Pemphigus Autoantibodies Indicates a Larger, More Diverse, and More Dynamic Repertoire than Determined by B Cell Genetics. , 2017, Cell reports.

[19]  C. Möbs,et al.  Research Techniques Made Simple: Monitoring of T-Cell Subsets using the ELISPOT Assay. , 2016, The Journal of investigative dermatology.

[20]  D. Zillikens,et al.  Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  M. Buc,et al.  HLA DRB1* and DQB1* alleles are associated with disease severity in patients with pemphigus vulgaris , 2015, International journal of dermatology.

[22]  M. Pan,et al.  Immune cellular regulation on autoantibody production in pemphigus , 2015, The Journal of dermatology.

[23]  R. Holmdahl,et al.  Pathogenic IgG Antibodies against Desmoglein 3 in Pemphigus Vulgaris Are Regulated by HLA-DRB1*04:02–Restricted T Cells , 2014, The Journal of Immunology.

[24]  K. Amber,et al.  Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris , 2013, Experimental dermatology.

[25]  A. Yoshimura,et al.  Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice. , 2011, The Journal of clinical investigation.

[26]  C. Massilamany,et al.  Detection of autoreactive CD4 T cells using major histocompatibility complex class II dextramers , 2011, BMC Immunology.

[27]  W. Uter,et al.  Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. , 2010, Clinical immunology.

[28]  Hayato Takahashi,et al.  A Single Helper T Cell Clone Is Sufficient to Commit Polyclonal Naive B Cells to Produce Pathogenic IgG in Experimental Pemphigus Vulgaris1 , 2009, The Journal of Immunology.

[29]  V. Sharma,et al.  Involvement of TH1/TH2 Cytokines in the Pathogenesis of Autoimmune Skin Disease—Pemphigus Vulgaris , 2009, Immunological investigations.

[30]  D. Zillikens,et al.  Pemphigus Vulgaris IgG Directly Inhibit Desmoglein 3-Mediated Transinteraction1 , 2008, The Journal of Immunology.

[31]  T. Nishikawa,et al.  Novel System Evaluating In Vivo Pathogenicity of Desmoglein 3-Reactive T Cell Clones Using Murine Pemphigus Vulgaris1 , 2008, The Journal of Immunology.

[32]  N. Shibagaki,et al.  CD4+CD25high Regulatory T Cells Are Markedly Decreased in Blood of Patients with Pemphigus Vulgaris , 2007, Dermatology.

[33]  M. Amagai,et al.  Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation. , 2006, The Journal of investigative dermatology.

[34]  R. Eming,et al.  T cell control in autoimmune bullous skin disorders. , 2006, The Journal of clinical investigation.

[35]  S. Chow,et al.  Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen‐specific Th2 activity in association with active disease , 2005, Clinical and experimental dermatology.

[36]  G. Schuler,et al.  Type I Regulatory T Cells Specific for Desmoglein 3 Are More Frequently Detected in Healthy Individuals than in Patients with Pemphigus Vulgaris1 , 2004, The Journal of Immunology.

[37]  Wolfgang Uter,et al.  T Cell Recognition of Desmoglein 3 Peptides in Patients with Pemphigus Vulgaris and Healthy Individuals1 , 2004, The Journal of Immunology.

[38]  B. Walker,et al.  Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. , 2003, The Journal of clinical investigation.

[39]  W. Uter,et al.  Dichotomy of Autoreactive Th1 and Th2 Cell Responses to Desmoglein 3 in Patients with Pemphigus Vulgaris (PV) and Healthy Carriers of PV-Associated HLA Class II Alleles1 , 2003, The Journal of Immunology.

[40]  T. Nishikawa,et al.  Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris , 2002, European journal of immunology.

[41]  D. Zillikens,et al.  IgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris , 2001, The British journal of dermatology.

[42]  M. Caproni,et al.  Further support for a role for Th2-like cytokines in blister formation of pemphigus. , 2001, Clinical immunology.

[43]  A. Ahmed,et al.  Presence of interleukin 10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid. , 2000, Cytokine.

[44]  L. Diaz,et al.  T lymphocytes from a subset of patients with pemphigus vulgaris respond to both desmoglein-3 and desmoglein-1. , 1997, The Journal of investigative dermatology.

[45]  J. Uitto,et al.  Targeted Disruption of the Pemphigus Vulgaris Antigen (Desmoglein 3) Gene in Mice Causes Loss of Keratinocyte Cell Adhesion with a Phenotype Similar to Pemphigus Vulgaris , 1997, The Journal of cell biology.

[46]  R. Karr,et al.  Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  N. Nagarwalla,et al.  Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Strominger,et al.  Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases , 1995, The Journal of experimental medicine.

[49]  T. Nishikawa,et al.  Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. , 1994, The Journal of clinical investigation.

[50]  P. Guinan,et al.  Serum immunoglobulin E in pemphigus. , 1978, The Journal of investigative dermatology.

[51]  D. Gordon,et al.  Disease relevant HLA class II alleles isolated by genotypic, haplotypic, and sequence analysis in North American Caucasians with pemphigus vulgaris. , 2006, Human immunology.

[52]  T. Nishikawa,et al.  Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model. , 2006, The Journal of investigative dermatology.

[53]  M. Amagai,et al.  Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. , 1998, The Journal of investigative dermatology.